Compare CELC & COLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | COLD |
|---|---|---|
| Founded | 2011 | 1903 |
| Country | United States | United States |
| Employees | N/A | 12690 |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2017 | 2009 |
| Metric | CELC | COLD |
|---|---|---|
| Price | $79.88 | $14.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 16 |
| Target Price | ★ $112.56 | $14.97 |
| AVG Volume (30 Days) | 759.7K | ★ 3.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 7.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,601,846,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $720.19 | $2.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.42 | $10.10 |
| 52 Week High | $151.02 | $16.88 |
| Indicator | CELC | COLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 51.33 |
| Support Level | $78.60 | $13.77 |
| Resistance Level | $96.39 | $15.36 |
| Average True Range (ATR) | 3.67 | 0.53 |
| MACD | -0.62 | 0.01 |
| Stochastic Oscillator | 14.44 | 75.00 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.